Asset Transaction, Regulation FD Disclosure (Form 8-K)

Item 2.01 - Completion of Acquisition or Disposition of Assets

On March 23, 2026, the Company completed the acquisition of one hundred percent (100%) of the issued and outstanding shares of Inversiones Long 33, C.A. pursuant to a Share Assignment Agreement with Kevin Rodan Levy. As a result of the foregoing, Inversiones Long 33, C.A. is a wholly-owned subsidiary of the Company. The Subsidiary was previously formed and is intended to serve as the Company's operating entity in Venezuela and as part of its broader Latin American strategy.

Item 7.01 - Regulation FD Disclosure

On March 23, 2026, March 26, 2026, April 7, 2026, April 9, 2026, and April 13, 2026, the Company issued press releases announcing (i) the establishment of its operating structure, (ii) the assignment of intellectual property, and (iii) the introduction of its CardioAI, PulmoAI, and NeuroAI platforms, which form part of the Company's artificial intelligence-enabled healthcare technology portfolio.

Copies of such press releases are available on publicly accessible platforms, including Yahoo Finance.

The information contained in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.